salvage therapy – Medxy AI

$Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights$

Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights

By MedXY 08/24/2026

A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostication.

Diabetes & Endocrinology news Oncology

Evaluating Pemetrexed Monotherapy and Combination Therapy with Carboplatin in Advanced Thyroid Cancer: A Retrospective Cohort Analysis

By MedXY 07/31/2026

This retrospective study assesses the efficacy and safety of pemetrexed, alone or combined with carboplatin, as salvage therapy for advanced thyroid cancer, showing promising response rates comparable to current second-line treatments.

news Oncology Urology

Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity

By MedXY 02/20/2026

A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications for patients with localized radiorecurrent prostate cancer.

$Venetoclax plus Azacitidine Emerges as a Potent Salvage Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia$

Hematology-Oncology news

Venetoclax plus Azacitidine Emerges as a Potent Salvage Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia

By MedXY 01/13/2026

A multicentre phase 2 trial demonstrates that the combination of venetoclax and azacitidine achieves a 76% overall response rate in relapsed or refractory T-ALL, offering a manageable and effective alternative for a patient population with traditionally poor prognoses.

Infectious Diseases news

Olorofim Offers a New Salvage Option for Drug‑Resistant Invasive Fungal Disease — Phase 2b Results

By MedXY 11/24/2025

Phase 2b data show olorofim has activity and acceptable tolerability in patients with invasive fungal disease and limited options, including azole‑resistant Aspergillus and intrinsically resistant moulds, supporting further controlled studies.